October 2, 2012
Sanofi's (NYSE: SNY ) Gaucher disease drug eliglutistat crushed its phase 3 trial, resoundingly beating a placebo and hitting all secondary endpoints as well. Sanofi is the king of Gaucher disease treatment, as its drug cerezyme is the current standard of care for this disease affecting about 6,000 people in the United States. However, cerezyme has to be infused, as does its new and cheaper competitor from Pfizer (NYSE: PFE ) and Protalix BioTherapeutics (NYSEMKT: PLX ) . Will a 25% discount make up for the fact that Sanofi's new drug is taken orally instead of injected? That's the company's hope, as it's counting on ease of use to stay one step ahead of the competition.
Check out the video for the full story on Sanofi's promising new treatment option. Remember, though, that while you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.